PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.

Active surveillance Consensus Prostate cancer Prostate magnetic resonance imaging

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
30 Mar 2024
Historique:
received: 02 01 2024
revised: 21 02 2024
accepted: 05 03 2024
medline: 1 4 2024
pubmed: 1 4 2024
entrez: 31 3 2024
Statut: aheadofprint

Résumé

The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations standardise the reporting of prostate magnetic resonance imaging (MRI) in patients on active surveillance (AS) for prostate cancer. An international consensus group recently updated these recommendations and identified the areas of uncertainty. A panel of 38 experts used the formal RAND/UCLA Appropriateness Method consensus methodology. Panellists scored 193 statements using a 1-9 agreement scale, where 9 means full agreement. A summary of agreement, uncertainty, or disagreement (derived from the group median score) and consensus (determined using the Interpercentile Range Adjusted for Symmetry method) was calculated for each statement and presented for discussion before individual rescoring. Participants agreed that MRI scans must meet a minimum image quality standard (median 9) or be given a score of 'X' for insufficient quality. The current scan should be compared with both baseline and previous scans (median 9), with the PRECISE score being the maximum from any lesion (median 8). PRECISE 3 (stable MRI) was subdivided into 3-V (visible) and 3-NonV (nonvisible) disease (median 9). Prostate Imaging Reporting and Data System/Likert ≥3 lesions should be measured on T2-weighted imaging, using other sequences to aid in the identification (median 8), and whenever possible, reported pictorially (diagrams, screenshots, or contours; median 9). There was no consensus on how to measure tumour size. More research is needed to determine a significant size increase (median 9). PRECISE 5 was clarified as progression to stage ≥T3a (median 9). The updated PRECISE recommendations reflect expert consensus opinion on minimal standards and reporting criteria for prostate MRI in AS. The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations are used in clinical practice and research to guide the interpretation and reporting of magnetic resonance imaging for patients on active surveillance for prostate cancer. An international panel has updated these recommendations, clarified the areas of uncertainty, and highlighted the areas for further research.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations standardise the reporting of prostate magnetic resonance imaging (MRI) in patients on active surveillance (AS) for prostate cancer. An international consensus group recently updated these recommendations and identified the areas of uncertainty.
METHODS METHODS
A panel of 38 experts used the formal RAND/UCLA Appropriateness Method consensus methodology. Panellists scored 193 statements using a 1-9 agreement scale, where 9 means full agreement. A summary of agreement, uncertainty, or disagreement (derived from the group median score) and consensus (determined using the Interpercentile Range Adjusted for Symmetry method) was calculated for each statement and presented for discussion before individual rescoring.
KEY FINDINGS AND LIMITATIONS UNASSIGNED
Participants agreed that MRI scans must meet a minimum image quality standard (median 9) or be given a score of 'X' for insufficient quality. The current scan should be compared with both baseline and previous scans (median 9), with the PRECISE score being the maximum from any lesion (median 8). PRECISE 3 (stable MRI) was subdivided into 3-V (visible) and 3-NonV (nonvisible) disease (median 9). Prostate Imaging Reporting and Data System/Likert ≥3 lesions should be measured on T2-weighted imaging, using other sequences to aid in the identification (median 8), and whenever possible, reported pictorially (diagrams, screenshots, or contours; median 9). There was no consensus on how to measure tumour size. More research is needed to determine a significant size increase (median 9). PRECISE 5 was clarified as progression to stage ≥T3a (median 9).
CONCLUSIONS AND CLINICAL IMPLICATIONS CONCLUSIONS
The updated PRECISE recommendations reflect expert consensus opinion on minimal standards and reporting criteria for prostate MRI in AS.
PATIENT SUMMARY RESULTS
The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations are used in clinical practice and research to guide the interpretation and reporting of magnetic resonance imaging for patients on active surveillance for prostate cancer. An international panel has updated these recommendations, clarified the areas of uncertainty, and highlighted the areas for further research.

Identifiants

DOI: 10.1016/j.eururo.2024.03.014 PMID: 38556436
pubmed: 38556436
pii: S0302-2838(24)02232-2
doi: 10.1016/j.eururo.2024.03.014
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Cameron Englman (C)

Division of Surgery & Interventional Science, University College London, London, UK; Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK.

Davide Maffei (D)

Division of Surgery & Interventional Science, University College London, London, UK; Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.

Clare Allen (C)

Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK.

Alex Kirkham (A)

Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK.

Peter Albertsen (P)

Department of Surgery (Urology), UConn Health, Farmington, CT, USA.

Veeru Kasivisvanathan (V)

Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.

Ronaldo Hueb Baroni (RH)

Department of Radiology, Hospital Israelita Albert Einstein. Sao Paulo, Brazil.

Alberto Briganti (A)

Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy.

Pieter De Visschere (P)

Department of Radiology and Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.

Louise Dickinson (L)

Division of Surgery & Interventional Science, University College London, London, UK; Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK.

Juan Gómez Rivas (J)

Department of Urology, Clinico San Carlos University Hospital, Madrid, Spain.

Masoom A Haider (MA)

Joint Department of Medical Imaging, Sinai Health System, University of Toronto, Toronto, Canada.

Claudia Kesch (C)

Department of Urology, University Hospital Essen, Essen, Germany.

Stacy Loeb (S)

Department of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs, New York, NY, USA.

Katarzyna J Macura (KJ)

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Daniel Margolis (D)

Weill Cornell Medical College, Department of Radiology, New York, NY, USA.

Anita M Mitra (AM)

Department of Cancer Services, University College London Hospitals NHS Foundation Trust, London, UK.

Anwar R Padhani (AR)

Paul Strickland Scanner Centre, Mount Vernon Hospital, Rickmansworth Road, Middlesex, UK.

Valeria Panebianco (V)

Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy.

Peter A Pinto (PA)

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Guillaume Ploussard (G)

Urology Department, La Croix du Sud Hospital, Quint Fonsegrives, France.

Philippe Puech (P)

Department of Radiology, University of Lille, Lille, France.

Andrei S Purysko (AS)

Abdominal Imaging Section, Imaging Institute, Cleveland Clinic, Cleveland, OH, USA.

Jan Philipp Radtke (JP)

University Dusseldorf, Medical Faculty, Department of Urology, Dusseldorf, Germany.

Antti Rannikko (A)

Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Art Rastinehad (A)

Department of Urology, Lenox Hill Hospital, New York, NY, USA.

Raphaele Renard-Penna (R)

Department of Radiology, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France.

Francesco Sanguedolce (F)

Department of Urology, Autonoma University of Barcelona, Barcelona, Spain; Department of Medicine, Surgery and Pharmacy, Universitá degli studi di Sassari - Italy.

Lars Schimmöller (L)

Dusseldorf University, Medical Faculty, Department of Diagnostic and Interventional Radiology, Dusseldorf, Germany; Department of Diagnostic, Interventional Radiology and Nuclear Medicine, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.

Ivo G Schoots (IG)

Department of Radiology & Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Shahrokh F Shariat (SF)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan.

Nicola Schieda (N)

Department of Radiology, University of Ottawa, Ottawa, ON, Canada.

Clare M Tempany (CM)

Department of Radiology Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Baris Turkbey (B)

Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Massimo Valerio (M)

Department of Urology, Geneva University Hospital, University of Geneva, Geneva, Switzerland.

Arnauld Villers (A)

Department of Urology, Hospital Claude Huriez, CHU Lille, Lille, France.

Jochen Walz (J)

Department of Urology, Institut Paoli-Calmettes Cancer Center, Marseille, France.

Tristan Barrett (T)

Department of Radiology, University of Cambridge, Addenbrook''s Hospital, Cambridge, UK.

Francesco Giganti (F)

Division of Surgery & Interventional Science, University College London, London, UK; Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK. Electronic address: f.giganti@ucl.ac.uk.

Caroline M Moore (CM)

Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.

Classifications MeSH